Studies

Showing 10 studies.

IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected Children >2 to <12 years of age and weighing >10 kgs and <50 kgs

Research Area

Study Status

IMPAACT 2024 : Phase I/II Dose Finding and Safety Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Infants, Children and Adolescents

DAIDS Number

Research Area

Study Status

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

Research Area

Complications & Comorbidities

Study Status

IMPAACT 2018: Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

Research Area

Complications & Comorbidities

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2013: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

Research Area

Complications & Comorbidities

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2012: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

Research Area

Complications & Comorbidities

Study Status

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

Research Area

Complications & Comorbidities

Study Status

IMPAACT 2007: Phase I Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

DAIDS Number

Research Area

Study Status

Closed to Follow Up

P1006: Effects of HAART on Immune Function

DAIDS Number

Research Area

Study Status